BWM
CRSP icon

BNC Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

BNC Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,964
Closed -$1.37M – 84
2020
Q4 		$1.37M Buy
8,964
+775
+9% +$91.6K 0.87% 37
2020
Q3 		$685K Buy
+8,189
New +$726K 0.48% 57

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BNC Wealth Management's CRSP Position: Q1 2021 in Review

BNC Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 8,964 shares — an estimated $1.37M sold.

BNC Wealth Management first reported a position in CRSP in Q3 2020 and held it in 2 quarters. The position peaked at $1.37M in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • BNC Wealth Management reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • BNC Wealth Management sold 8,964 CRISPR Therapeutics shares in Q1 2021, an estimated $1.37M.
  • BNC Wealth Management first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 2 quarters.
  • BNC Wealth Management's CRISPR Therapeutics position peaked at $1.37M in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on BNC Wealth Management's 13F filing for Q1 2021, filed 19 May 2021.